首页> 外文期刊>Breast Cancer Research >Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth
【24h】

Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth

机译:抑制人类乳腺癌细胞系中的miR-21可抑制增殖,体外迁移和体内肿瘤生长

获取原文
           

摘要

IntroductionMicroRNAs (miRNAs) are a class of small non-coding RNAs (20 to 24 nucleotides) that post-transcriptionally modulate gene expression. A key oncomir in carcinogenesis is miR-21, which is consistently up-regulated in a wide range of cancers. However, few functional studies are available for miR-21, and few targets have been identified. In this study, we explored the role of miR-21 in human breast cancer cells and tissues, and searched for miR-21 targets.MethodsWe used in vitro and in vivo assays to explore the role of miR-21 in the malignant progression of human breast cancer, using miR-21 knockdown. Using LNA silencing combined to microarray technology and target prediction, we screened for potential targets of miR-21 and validated direct targets by using luciferase reporter assay and Western blot. Two candidate target genes (EIF4A2 and ANKRD46) were selected for analysis of correlation with clinicopathological characteristics and prognosis using immunohistochemistry on cancer tissue microrrays.ResultsAnti-miR-21 inhibited growth and migration of MCF-7 and MDA-MB-231 cells in vitro, and tumor growth in nude mice. Knockdown of miR-21 significantly increased the expression of ANKRD46 at both mRNA and protein levels. Luciferase assays using a reporter carrying a putative target site in the 3' untranslated region of ANKRD46 revealed that miR-21 directly targeted ANKRD46. miR-21 and EIF4A2 protein were inversely expressed in breast cancers (rs = -0.283, P = 0.005, Spearman's correlation analysis).ConclusionsKnockdown of miR-21 in MCF-7 and MDA-MB-231 cells inhibits in vitro and in vivo growth as well as in vitro migration. ANKRD46 is newly identified as a direct target of miR-21 in BC. These results suggest that inhibitory strategies against miR-21 using peptide nucleic acids (PNAs)-antimiR-21 may provide potential therapeutic applications in breast cancer treatment.
机译:简介MicroRNA(miRNA)是一类小的非编码RNA(20至24个核苷酸),可在转录后调节基因表达。 miR-21是致癌作用中的关键致病因素,它在多种癌症中均被上调。但是,很少有功能研究可用于miR-21,并且几乎没有发现靶标。在这项研究中,我们探索了miR-21在人类乳腺癌细胞和组织中的作用,并寻找了miR-21靶标。方法我们使用了体内和体外实验来探讨miR-21在人类恶性进展中的作用。乳腺癌,使用miR-21基因敲低。使用结合了微阵列技术的LNA沉默和靶标预测,我们筛选了miR-21的潜在靶标,并通过荧光素酶报告基因检测和Western blot验证了直接靶标。使用免疫组织化学方法对癌组织微射线选择了两个候选靶基因(EIF4A2和ANKRD46)进行临床病理特征与预后的相关性分析。结果抗miR-21抑制了MCF-7和MDA-MB-231细胞的生长和迁移,和裸鼠的肿瘤生长。敲除miR-21可以显着提高mRNA和蛋白水平上ANKRD46的表达。使用在ANKRD46的3'非翻译区带有推定靶位点的报告基因进行的萤光素酶检测显示,miR-21直接靶向ANKRD46。 miR-21和EIF4A2蛋白在乳腺癌中呈负相关表达(rs = -0.283,P = 0.005,Spearman相关分析)。结论miR-21在MCF-7和MDA-MB-231细胞中的抑制作用可抑制体内和体外生长。以及体外迁移。 ANKRD46被新确定为BC中miR-21的直接靶标。这些结果表明,使用肽核酸(PNA)-antimiR-21抑制miR-21的策略可能在乳腺癌治疗中提供潜在的治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号